Review: Cardiopulmonary Event Rate Not Up With Propofol Use
Similar risk with propofol versus traditional sedation for gastrointestinal endoscopic procedures
TUESDAY, Jan. 31, 2017 (HealthDay News) -- The risk of cardiopulmonary adverse events is similar for propofol sedation and traditional sedation agents for gastrointestinal endoscopic procedures, according to a review published in the February issue of Clinical Gastroenterology and Hepatology.
Vaibhav Wadhwa, M.D., from Fairview Hospital in Cleveland, and colleagues conducted a systematic review to compare sedation-related adverse events associated with use of propofol versus non-propofol agents for endoscopic procedures. The procedures were categorized into two groups based on procedure length: a non-advanced endoscopic procedure group and an advanced endoscopic procedure group. Data were included for 27 studies with 2,518 patients (1,324 received propofol and 1,194 received midazolam, meperidine, pethidine, remifentanil, and/or fentanyl).
The researchers found that the pooled odds ratio with use of propofol versus traditional sedative agents was 0.82 (95 percent confidence interval, 0.63 to 1.07) for developing hypoxia for all procedures combined and 0.92 (95 percent confidence interval, 0.64 to 1.32) for developing hypotension. Those who received propofol were less likely to develop complications than those receiving traditional sedative agents in the non-advanced endoscopic group (odds ratio, 0.61; 95 percent confidence interval, 0.38 to 0.99). The advanced endoscopic procedure group had no difference in the complication rate (odds ratio, 0.86; 95 percent confidence interval, 0.56 to 1.34).
"Propofol sedation has a similar risk of cardiopulmonary adverse events compared with traditional agents for gastrointestinal endoscopic procedures," the authors write.